Seratrodast
CAS: 112665-43-7
Ref. TM-T0212
10mg | 56.00 € | ||
25mg | 76.00 € | ||
50mg | 97.00 € | ||
100mg | 142.00 € | ||
200mg | 176.00 € | ||
500mg | 277.00 € | ||
1ml*10 (DMSO) | 52.00 € |
Product Information
- AA 2414, ABT-001
- (+-)-2,4,5-Trimethyl-3,6-dioxo-zeta-phenyl-1,4-cyclohexadiene-1-heptanoic acid
- (+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid
- (±)-2,4,5-Trimethyl-3,6-dioxo-ζ-phenyl-1,4-cyclohexadiene-1-heptanoic acid
- 7-(2,4,5-Trimethyl-3,6-Dioxocyclohexa-1,4-Dienyl)-7-Phenylheptanoic Acid
- 7-Phenyl-7-(2,4,5-Trimethyl-3,6-Dioxocyclohexa-1,4-Dien-1-Yl)Heptanoic Acid
- A 73001
- Aa-2414
- Abbott 73001
- Abt 001
- See more synonyms
- Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)-
- Benzeneheptanoic acid, ζ-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-
- Bronica
- Ccris 8939
- Seratodrast
- Seratrodast [USAN:INN]
- Unii-4U58Jm421N
- methyl 5-amino-1-methyl-1H-pyrazole-4-carboxylate
- ζ-(2,4,5-Trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)benzeneheptanoic acid
Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.
Chemical properties
Technical inquiry about: TM-T0212 Seratrodast
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.